Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

Two Dose Levels of Privigen in Pediatric CIDP

Phase 4

Recruiting

Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Interventions: Biological: IgPro10

First Posted Date: 2018-09-25

Last Posted Date: 2025-06-24

Lead Sponsor: CSL Behring

Target Recruit Count: 30

Registration Number: NCT03684018

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 6 locations

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

Phase 3

Completed

Conditions: Hemophilia B

Interventions: Genetic: AAV5-hFIXco-Padua
Biological: Factor IX (FIX)

First Posted Date: 2018-06-26

Last Posted Date: 2025-05-04

Lead Sponsor: CSL Behring

Target Recruit Count: 67

Registration Number: NCT03569891

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Los Angeles Orthopedic Hospital, Los Angeles, California, United States

and more 30 locations

Dose Confirmation Trial of AAV5-hFIXco-Padua

Phase 2

Completed

Conditions: Hemophilia B

Interventions: Genetic: AAV5-hFIXco-Padua (AMT-061)

First Posted Date: 2018-04-05

Last Posted Date: 2024-06-28

Lead Sponsor: CSL Behring

Target Recruit Count: 3

Registration Number: NCT03489291

Locations: 🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
University of California, Davis, Sacramento, California, United States
🇺🇸
University of California, San Diego, San Diego, California, United States

and more 1 locations

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Other: Placebo
Biological: Apolipoprotein A-I [human] (apoA-I)

First Posted Date: 2018-03-22

Last Posted Date: 2025-01-14

Lead Sponsor: CSL Behring

Target Recruit Count: 18226

Registration Number: NCT03473223

Locations: 🇺🇸
8400896 - Advanced Cardiovascular LLC, Alexander City, Alabama, United States
🇺🇸
8400350 - Cardiology, PC, Birmingham, Alabama, United States
🇺🇸
8400337 - Heart Center Research, LLC, Huntsville, Alabama, United States

and more 900 locations

Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults

Phase 1

Terminated

Conditions: Healthy

Interventions: Other: Placebo
Biological: CSL730

First Posted Date: 2017-12-18

Last Posted Date: 2021-06-03

Lead Sponsor: CSL Behring

Target Recruit Count: 26

Registration Number: NCT03375606

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands
🇬🇧
Hammersmith Medicines Research, London, United Kingdom

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Phase 3

Terminated

Conditions: Antibody-mediated Rejection

Interventions: Drug: Placebo
Drug: C1-esterase inhibitor

First Posted Date: 2017-07-19

Last Posted Date: 2022-07-29

Lead Sponsor: CSL Behring

Target Recruit Count: 63

Registration Number: NCT03221842

Locations: 🇺🇸
University of Alabama Hospital (at Birmingham), Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
California Pacific, San Francisco, California, United States

and more 23 locations

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Phase 4

Completed

Conditions: Primary Immunodeficiency

Interventions: Drug: IgPro20

First Posted Date: 2017-01-27

Last Posted Date: 2020-03-25

Lead Sponsor: CSL Behring

Target Recruit Count: 49

Registration Number: NCT03033745

Locations: 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸
Research Solutions of Arizona, Litchfield Park, Arizona, United States
🇺🇸
University of Southern Florida, Saint Petersburg, Florida, United States

and more 9 locations

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Phase 2

Completed

Conditions: Moderate Renal Impairment
Acute Myocardial Infarction

Interventions: Other: Placebo
Biological: CSL_112

First Posted Date: 2016-04-18

Last Posted Date: 2020-06-11

Lead Sponsor: CSL Behring

Target Recruit Count: 83

Registration Number: NCT02742103

Locations: 🇺🇸
Study Site 16101, Birmingham, Alabama, United States
🇺🇸
Study Site 16078, Huntsville, Alabama, United States
🇺🇸
Study Site 16168, Concord, California, United States

and more 28 locations

Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

Phase 4

Completed

Conditions: Primary Immune Deficiency
Secondary Immune Deficiency

Interventions: Biological: Subcutaneous Immune Globulin (Human) (Hizentra)

First Posted Date: 2016-03-17

Last Posted Date: 2018-02-26

Lead Sponsor: CSL Behring

Target Recruit Count: 26

Registration Number: NCT02711228

Locations: 🇨🇦
Centre Hospitalier de l'université de Montréal, Montreal, Canada
🇨🇦
CHU Sainte-Justine, Montreal, Canada

Study of Voncento® in Subjects With Von Willebrand Disease

Phase 4

Completed

Conditions: Von Willebrand Disease

Interventions: Biological: Voncento

First Posted Date: 2015-09-17

Last Posted Date: 2018-05-16

Lead Sponsor: CSL Behring

Target Recruit Count: 26

Registration Number: NCT02552576

Locations: 🇵🇱
Study Site, Wroclaw, Poland
🇬🇧
Study Site 14, London, United Kingdom
🇬🇧
Study Site 40, London, United Kingdom

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy